Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Mallinckrodt
McKesson

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Evobrutinib


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Evobrutinib?

Evobrutinib is an investigational drug.

There have been 17 clinical trials for Evobrutinib. The most recent clinical trial was a Phase 2 trial, which was initiated on August 26th 2019.

The most common disease conditions in clinical trials are Sclerosis, Multiple Sclerosis, and Multiple Sclerosis, Relapsing-Remitting. The leading clinical trial sponsors are Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc., and Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany.

There are nine US patents protecting this investigational drug and one hundred and twenty-three international patents.

Recent Clinical Trials for Evobrutinib
TitleSponsorPhase
Drug-Drug Interaction Study of Evobrutinib and Transporter SubstratesMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyPhase 1
Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy ParticipantsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyPhase 1
Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PKMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyPhase 1

See all Evobrutinib clinical trials

Clinical Trial Summary for Evobrutinib

Top disease conditions for Evobrutinib
Top clinical trial sponsors for Evobrutinib

See all Evobrutinib clinical trials

US Patents for Evobrutinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Evobrutinib ⤷  Try it Free Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity Merck Patent GmbH (Darmstadt, DE) ⤷  Try it Free
Evobrutinib ⤷  Try it Free Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity Merck Patent GmbH (Darmstadt, DE) ⤷  Try it Free
Evobrutinib ⤷  Try it Free Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidi- n-1-yl)-propenone Merck Patent GmbH (Darmstadt, DE) ⤷  Try it Free
Evobrutinib ⤷  Try it Free Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidi- n-1-yl)-propenone Merck Patent GmbH (Darmstadt, DE) ⤷  Try it Free
Evobrutinib ⤷  Try it Free PD-1/PD-L1 inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Evobrutinib

Drugname Country Document Number Estimated Expiration Related US Patent
Evobrutinib Australia AU2012267491 2031-06-10 ⤷  Try it Free
Evobrutinib Australia AU2017235978 2031-06-10 ⤷  Try it Free
Evobrutinib Brazil BR112013030442 2031-06-10 ⤷  Try it Free
Evobrutinib Canada CA2833771 2031-06-10 ⤷  Try it Free
Evobrutinib China CN103814016 2031-06-10 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.